QIAGEN Views – Insights from our leadership team
-
Daniel Schatz, CISO | April 21, 2022Investing in cybersecurity is more important than everThe last few years have seen major shifts in online threats. All companies – including those in biotech – have to take this seriously and respond. -
Thierry Bernard, CEO | January 20, 2022We need a huge push to prevent Phi, Rho and SigmaWith Omicron rapidly spreading around the world, we need to learn from our mistakes to prevent emergence of future SARS-CoV-2 variants. -
Thierry Bernard, CEO | May 25, 2021With focus on the COVID-19 pandemic, the world has taken its eye off TBTuberculosis is highly infectious and a global problem that COVID-19 has only made worse. Two legacies of the response to COVID-19 give rise to hope. -
Jürgen Schneider, Head of IP & L | September 6, 2021RNA, DNA and the rising cost of IP managementAdvances in molecular testing are making patent protection and monitoring ever more difficult. It is time for the sector to reach for new tools. -
Thierry Bernard, CEO | March 5, 2021A modern healthcare system should invest in diagnostics and testingThe COVID-19 pandemic might yet have an upside: more prevention-driven healthcare. -
Stephany Foster, Head of HR | December 16, 2021Empower your careerMaking a lateral move to a different department or function can allow you to explore a new opportunity without having to start over completely.